| Debbie Cozier, | |
|
1818 New York Ave Ne, 228, Washington, DC 20002-1848 | |
| (202) 832-8340 | |
| Not Available |
| Full Name | Debbie Cozier |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1818 New York Ave Ne, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134488372 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LPN7945 (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Debbie Cozier, 1818 New York Ave Ne, 228, Washington, DC 20002-1848 Ph: () - | Debbie Cozier, 1818 New York Ave Ne, 228, Washington, DC 20002-1848 Ph: (202) 832-8340 |
News Archive
Despite an enormous range of treatments, obscure lotions and tinctures there appears to be very few successful counter-measures for hair loss in men. Beginning with receding hairlines, every second man suffers from hair loss to some degree, and it has always been suspected that hereditary factors are important in causing hair loss.
Researchers from the US recently described a rapid molecular test named WHotLAMP for the detection of SARS-CoV-2 in saliva. WHotLAMP is easy to use, very sensitive at 3.6 viral RNA copies per microliter of saliva, specific, and inexpensive. This study is published on the medRxiv*preprint serve.
Human Genome Sciences, Inc. today announced the closing of its public offering of 17,825,000 newly issued shares of its common stock at a price to the public of $26.75 per share, which includes 2,325,000 shares sold upon exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company from the offering are approximately $456.3 million, after deducting the underwriting discount and estimated offering expenses.
Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
› Verified 8 days ago
Emmanuel Mbu, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2811 Pennsylvania Ave Se, Washington, DC 20020 Phone: 301-379-8449 | |
Stella Segun, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw, Suite 220, Washington, DC 20012 Phone: 202-545-6980 | |
Yolanda Blagrove, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 801 Pennsylvania Ave Se, Washington, DC 20003 Phone: 202-796-0605 | |
Nwaneka Onuaku, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw Ste 320a, Washington, DC 20012 Phone: 202-541-9844 | |
Priscillia N Moghalu, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw, Washington, DC 20012 Phone: 202-541-9844 | |
Jasmine Rhodes, HHA, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 505 Madison St Nw, Washington, DC 20011 Phone: 202-600-6972 | |
Rochelle Fadare, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 7600 Georgia Ave Nw Ste 323, Washington, DC 20012 Phone: 202-723-3060 Fax: 202-723-3065 |